Avet Pharma Annouces The Launch of Prochlorperazine Injection
Eatontown, NJ, January 16, 2014. Avet Pharmaceuticals Inc. announced the immediate availability of Prochlorperazine Edisylate Injection in the 5mg/mL strength. This product is the AP rated generic equivalent to the former brand Compazine and adds to Avet’s growing portfolio of generic injectable prescription products. According to IMS data for the twelve-months ended December 2013, the U.S. market for Prochlorperazine Edisylate Injection approximated $5.5 million.